Teva Pharmaceutical Industries (TEVA) Stock Price, News & Analysis

Company Overview

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms. The company also develops biosimilar medicines and provides pharmaceutical ingredients to support drug manufacturing.

Founded in Jerusalem in 1901, Teva has grown into an international pharmaceutical business serving patients and healthcare providers in markets across North America, Europe and other regions worldwide. Richard Francis has served as Teva’s president and chief executive officer since January 2023.

Key Stats

• Today's Range: $36.06 to $37.11
• 50-Day Range: $30.19 to $38.02
• 52-Week Range: $18.21 to $38.37
• Volume: 2.86 million shs
• Average Volume: 4.56 million shs
• Market Capitalization: $43.13 billion
• P/E Ratio: 61.68
• Dividend Yield: N/A
• Price Target: $43.10
• Consensus Rating: Moderate Buy

Teva Pharmaceutical Industries Stock Analysis - MarketRank™

Teva Pharmaceutical Industries scored higher than 78% of companies evaluated by MarketBeat, and ranked 146th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Teva Pharmaceutical Industries has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on no strong buy ratings, 10 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Teva Pharmaceutical Industries has a consensus price target of $43.10, representing about 16.5% upside from its current price of $37.01.

Amount of Analyst Coverage

Teva Pharmaceutical Industries has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 55.15%

Earnings Growth

Earnings for Teva Pharmaceutical Industries are expected to grow by 55.15% in the coming year, from $1.94 to $3.01 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Teva Pharmaceutical Industries is 61.68, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.11.

Price to Earnings Ratio vs. Sector

The P/E ratio of Teva Pharmaceutical Industries is 61.68, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.98.

Price to Earnings Growth Ratio

Teva Pharmaceutical Industries has a PEG Ratio of 4.53. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Teva Pharmaceutical Industries has a P/B Ratio of 5.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.25% of the float of Teva Pharmaceutical Industries has been sold short.

Short Interest Ratio / Days to Cover

Teva Pharmaceutical Industries has a short interest ratio ("days to cover") of 7.71.

Change versus previous month

Short interest in Teva Pharmaceutical Industries has recently increased by 5.45%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: N/A

Dividend Yield

Teva Pharmaceutical Industries does not currently pay a dividend.

Dividend Growth

Teva Pharmaceutical Industries does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Teva Pharmaceutical Industries will have a dividend payout ratio of 33.59% next year. This indicates that Teva Pharmaceutical Industries will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.73

News Sentiment

Teva Pharmaceutical Industries has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Teva Pharmaceutical Industries this week, compared to 9 articles on an average week.

Search Interest

Only 6 people have searched for TEVA on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Teva Pharmaceutical Industries to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Teva Pharmaceutical Industries insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $593.00 in company stock.

Percentage Held by Insiders

0.54% of the stock of Teva Pharmaceutical Industries is held by insiders.

Percentage Held by Institutions

54.05% of the stock of Teva Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 6/30/2026
• Today: 9/12/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/14/2026
• Barclays 24th Annual Global Financial Services Conference: 9/14/2026
• U.S. All Stars Conference: 9/22/2026
• Bank of America Global Healthcare Conference: 9/23/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:TEVA
• CIK: 818686
• Web: www.tevapharm.com
• Phone: (723) 914-8213
• Fax: 972-3923-4050
• Employees: 33,950
• Year Founded: 1901

Price Target and Rating

• Average Price Target for Teva Pharmaceutical Industries: $43.10
• High Price Target: $48.00
• Low Price Target: $40.00
• Potential Upside/Downside: +16.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.60
• Trailing P/E Ratio: 61.68
• Forward P/E Ratio: 19.08
• P/E Growth: 4.53
• Net Income: $1.41 billion
• Net Margins: 4.08%
• Pretax Margin: 4.09%
• Return on Equity: 32.64%
• Return on Assets: 6.34%

Debt

• Debt-to-Equity Ratio: 1.56
• Current Ratio: 0.88
• Quick Ratio: 0.67

Sales & Book Value

• Annual Sales: $17.26 billion
• Price / Sales: 2.50
• Cash Flow: $3.80 per share
• Price / Cash Flow: 9.74
• Book Value: $6.88 per share
• Price / Book: 5.38

Miscellaneous

• Outstanding Shares: 1,165,300,000
• Free Float: 1,159,003,000
• Market Cap: $43.13 billion
• Optionable: Optionable
• Beta: 0.87